Access brought to you by: LOCKSS

Hyperglycemia/Hypoglycemia

Cardiovascular Safety of Linagliptin in Patients with Type 2 Diabetes
Empagliflozin Improves Glycemic Parameters and Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus
Update on the New Insulin Preparations
Insulin Dose Not Linked to Cardiovascular Mortality in the ACCORD Trial
Education Improves Hypoglycemia Awareness Regardless of Technology Used for Insulin Delivery
ORIGIN Trial: Insulin Glargine and n-3 Fatty Acids Neither Reduces CV Events Nor Increases Cancers in Diabetic Patients
Linagliptin Proves Safe and Effective as Add-on Therapy to Basal Insulin
12-Week Treatment with LY2409021 Significantly Lowers HbA1C and Is Well Tolerated in Patients with Type 2 Diabetes Mellitus
Insulin Degludec is Superior to Sitagliptin in Improving Glycemic Control in Uncontrolled Patients with Type 2 Diabetes on Oral Agents
Extending the Reach of GLP-1

Pages